Meeting Materials
The secure way to view our annual documents
and to vote your shares.
Your vote is important! Vote your proxy online now or by phone by dialing 800-454-8683.
June 13, 2023
10:00 a.m. Eastern Time
Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
